The Effect of a Liraglutide on IVF in Obese PCOS

NCT03353948 · Completed

Last updated 2026-05-28

This clinical trial is testing whether the medication liraglutide improves pregnancy rates from in vitro fertilization (IVF) in women who have polycystic ovary syndrome (PCOS), obesity, and infertility.

Status Completed The study has finished.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 30 people

Who can join Ages 18–37 · female only

Timeline Started 2014-09 · est. completion 2016-09

What this study is testing ClinicalTrials.gov NCT03353948 ↗

Description as written by the study sponsor.

The aim of this study was to evaluate the impact of low dose liraglutide in combination with metformin compared to metformin alone on IVF pregnancy rate (PR) and cumulatively PR (IVF and spontaneous) in infertile obese women with PCOS who had been previously poor responders regarding weight reduction with lifestyle modification and resistant to first line reproductive treatments.

Treatments tested

MET also known as Glucophage tbl Drug

In the MET group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg BID per os for 12 weeks. After 1 month IVF was done.
COMBI also known as Victoza 6 mg/ml solution for injection in pre-filled pen Drug

In the COMBI group the initial dose of MET was 500 mg for at least 2 wk and gradually increased to a final dose of 1000 mg BID. Liraglutide 1.2 mg QD s.c. was added after first two weeks of monotherapy with MET. After 1 month IVF was done.

Main thing measured	IVF pregnancy rates
Sponsor	University Medical Centre Ljubljana
Conditions studied	Polycystic Ovary Syndrome, Obesity, Infertility, Female
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03353948 ↗